Clinical trials: Nonalcoholic Fatty Liver
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo
- Trial name
- NCT02605616
- Testing
- AZ compound
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- University of Alabama at Birmingham
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study
Several diets have been proposed to reduce liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD), and various effects on liver steatosis have been observed.
- Trial name
- NCT05309642
- Testing
- Intermittent calorie restriction, Standard of care
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Type 2 Diabetes
Longitudinal Assessment of Multiple Organs in Patients With Type 2 Diabetes
MODIFY study is a multi-centre prospective, longitudinal, observational cohort study which aims to recruit 150 adult patients with type 2 diabetes recruited from community, primary care or secondary care settings.
- Trial name
- MODIFY (NCT04114682)
- Testing
- Multi parametric MRI scan
- Where
- 4 sites in United Kingdom
- Volunteers
- 135 people
- Sponsor
- Perspectum
Non Alcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
Fatty liver disease is an increasingly recognized health problem in patients with type 2 diabetes mellitus (T2DM). Sodium glucose co-transporter type 2 (SGLT-2) inhibitors are a new class of anti-diabetic agents that cause weight…
- Trial name
- E-LIFT (NCT02686476)
- Testing
- Empagliflozin
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Medanta, The Medicity, India
NAFLD
Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
The investigators will conduct a proof-of-principle 4-weeks low-calorie diet (LCD) intervention study in low birth weight (LBW) subjects and normal birth weight (NBW) controls with documented (MR scan) liver fat content equal to…
- Trial name
- NCT05842850
- Testing
- Caloric restriction intervention, No intervention
- Where
- 2 sites in Denmark
- Volunteers
- 8 people
- Sponsor
- Steno Diabetes Center Copenhagen
Fatty Liver Disease
Effect of Thyroid Disorders in Liver Diseases
Aims of the Research 1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD). 2. To detect hepatic risk in subclinical and clinical hypothyroidism . 3.
- Trial name
- NCT06071923
- Testing
- Fibroscan
- Volunteers
- 140 people
- Sponsor
- Assiut University
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2
Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide and is a major cause of cirrhosis and liver cancer in Western countries.
- Trial name
- NCT04241575
- Testing
- Simple fibrosis scores and electronic reminder messages
- Where
- Hong Kong
- Volunteers
- 1,061 people
- Sponsor
- Chinese University of Hong Kong
Non-Alcoholic Fatty Liver Disease
Serum Ferritin as a Non-invasive Marker in Prediction of Hepatic Fibrosis Among NAFLD Patients
This study was designed to assess the relation between serum ferritin and hepatic fibrosis in patients with NAFLD. It included 83 patients with NAFLD with or without hepatic fibrosis, in addition to 30 healthy subjects included…
- Trial name
- NCT03250572
- Testing
- serum ferritin
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver biochemistry tests in the world. The prevalence rate of NAFLD has been reported to be 30-40% in men and 15-20% in women, up to 70% of people with…
- Trial name
- NCT04059029
- Testing
- Bariatric surgery
- Volunteers
- 200 people
- Sponsor
- Taipei Medical University Hospital
Hepatic Steatosis
A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease
The goal of this clinical trial is to learn if Longqi Jiangzhi decoction works to treat non-alcoholic fatty liver disease in adults. It will also learn about the safety of drug Longqi Jiangzhi decoction.
- Trial name
- NCT07320456
- Testing
- Longqi Jiangzhi decoction
- Volunteers
- 80 people
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
Non Alcoholic Fatty Liver Disease
Effects of Turkish Coffee and Green Tea in Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a common liver condition associated with metabolic disorders and lifestyle factors.
- Trial name
- NCT07768956
- Testing
- green tea, Turkish Coffee, mediterranean diet
- Where
- Turkey (Türkiye)
- Volunteers
- 47 people
- Sponsor
- Okan University
Menopause, Non Alcholic Fatty Liver Disease
MHT and Liver Function in Postmenopausal Women
This prospective study aims to evaluate the effects of menopausal hormone therapy (MHT) on liver function, lipid profiles, and hepatic steatosis in postmenopausal women.
- Conditions
- Menopause, Non Alcholic Fatty Liver Disease, Hepatic Steatosis
- Trial name
- NCT07103603
- Testing
- Menopausal hormone therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Ipek B. Ozcivit Erkan, MD
Non-alcoholic Fatty Liver Disease
6-week Safety and PD Study in Adults With NAFLD
IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH…
- Trial name
- NCT03256526
- Testing
- PF-06835919 Low Dose, PF-06835919 High Dose
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Non-Alcoholic Fatty Liver Disease, Obesity
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
This will be a 6-month randomized clinical trial with two arms: moderately carbohydrate-restricted diet and a fat-restricted control diet.
- Trial name
- NCT05268042
- Testing
- Moderately carbohydrate-restricted diet, Fat-restricted diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Alabama at Birmingham
Non-alcoholic Fatty Liver Disease (NAFLD)
Study to Evaluate the Effectiveness of Legalon®
This is a multinational, multicentre, prospective, non-interventional study (NIS) in non-alcoholic fatty liver disease (NAFLD) patients with concomitant metabolic syndrome treated with Legalon® combined with diet and exercise.
- Trial name
- NCT05051527
- Testing
- Legalon® 140 mg
- Where
- Thailand
- Volunteers
- 362 people
- Sponsor
- Mylan Inc.
NAFLD
Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents
Fatty liver disease is an increasing problem in overweight and obese young adults. The purpose of this study is to test the effect of growth hormone on liver fat in obese young adults ages 18-29y with increased liver fat.
- Trial name
- NCT02726542
- Testing
- somatropin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Non-alcoholic Steatohepatitis
A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
This study looks at how a new medicine called NNC0194-0499 works in the body of Japanese men and non-Asian men. Japanese participants will either get NNC0194-0499 or placebo - which treatment participants get is decided by…
- Trial name
- NCT04722653
- Testing
- NNC0194-0499
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
NAFLD, Metabolic Syndrome
Dietary Supplementation With Butyrate in Individuals With Liver Steatosis and Metabolic Syndrome
This was a double-blind, randomized, placebo-controlled clinical study aiming to assess the effect of a food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3 on liver…
- Trial name
- NCT06398522
- Testing
- Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Bologna
MASLD, MASH
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of denifanstat 50 mg compared to placebo in patients with metabolic dysfunction-associated steatotic liver disease…
- Conditions
- MASLD, MASH, NASH, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- FASCINIT (NCT06692283)
- Testing
- denifanstat
- Sponsor
- Sagimet Biosciences Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.